Holger Lode

Has grant

Professor and Chair of Pediatrics

University Medicine Greifswald

Germany

Research Interests

Explore related searches

Professors in Germany Professors in Immunology Immunology professors in Germany

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Holger Lode is a Professor and Chair of Pediatrics at the University Medicine Greifswald in Germany. His research focuses on pediatric oncology, particularly on treatments for high-risk neuroblastoma, including the use of anti-GD2 immunotherapy and novel chemotherapy protocols. His recent publications include studies on the efficacy and safety of dinutuximab beta and its correlation with patient outcomes in various treatment settings.

Recent Grants

Grant: Close

DNA-Impfstoffe zur Immuntherapie maligner Erkrankungen am Beispiel des schwach immunogenen Neuroblastoms

Open Date: 2000-01-01

Close Date: 2008-12-31

Grant: Close

MOLECULAR PROFILE OF MELANOMA AND NEUROBLASTOMA ANTIGENS

Open Date: 1986-06-01

Close Date: 2001-03-31

Articles (17)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Collaborators (10)

Angelika Eggert

Full Professor of Pediatrics & Director

Charité - Universitätsmedizin Berlin

GERMANY

View details

William Anderson

University College London

UNITED KINGDOM

View details

Bernhard Rauch

Professor, Division Head

Carl von Ossietzky Universität Oldenburg

GERMANY

View details

Adela Cañete

professor

Universitat Politècnica de València

SPAIN

View details

Johannes Hubertus Schulte

Head of Pediatric Stem Cell Transplantation; Professor of Pediatric Oncology Research

Charité Universitätsmedizin Berlin - Campus Virchow-Klinikum

GERMANY

View details

Lea Miebach

Leibniz-Institut für Plasmaforschung und Technologie eV

GERMANY

View details

Matthias Eyrich

Prof. Dr. med.

University of Wuerzburg

GERMANY

View details

Peter Lang

GERMANY

View details

Eric Freund

Leibniz-Institut für Plasmaforschung und Technologie eV

GERMANY

View details

Aleksandra Wieczorek

Jagiellonian University Medical College

POLAND

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Holger Lode

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (17)

Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial

Dinutuximab Beta Versus Naxitamab in the Treatment of Relapsed/Refractory Neuroblastoma in Patients with Stable Disease, Minor Response or Partial Response and Disease in Bone or Bone Marrow: Systematic Review and Matching-Adjusted Indirect Comparison

Affinity Affects the Functional Potency of Anti-GD2 Antibodies by Target-Mediated Drug Disposition

Efficacy and Safety of Anti-GD2 Immunotherapy with Dinutuximab Beta in the Treatment of Relapsed/Refractory High-Risk Neuroblastoma

Long-Term Outcomes and Quality of Life of High-Risk Neuroblastoma Patients Treated with a Multimodal Treatment Including Anti-GD2 Immunotherapy: A Retrospective Cohort Study

Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II Trial.

Effect and Tolerance of N5 and N6 Chemotherapy Cycles in Combination with Dinutuximab Beta in Relapsed High-Risk Neuroblastoma Patients Who Failed at Least One Second-Line Therapy

Pediatric Hematology and Oncology Center Integrated by Telemedicine: Experience, Challenges and First Results of a Cross Border Network

Quantitative Diffusion-Weighted MRI of Neuroblastoma

Chemotherapeutics Used for High-Risk Neuroblastoma Therapy Improve the Efficacy of Anti-GD2 Antibody Dinutuximab Beta in Preclinical Spheroid Models

Multimodal Therapy with Consolidating Haploidentical Stem Cell Transplantation and Dinutuximab Beta for Patients with High-Risk Neuroblastoma and Central Nervous System Relapse

Long-term, continuous infusion of single-agent dinutuximab beta for relapsed/refractory neuroblastoma: an open-label, single-arm, Phase 2 study

Immunophenotyping of Circulating and Intratumoral Myeloid and T Cells in Glioblastoma Patients

Immune Response and Outcome of High-Risk Neuroblastoma Patients Immunized with Anti-Idiotypic Antibody Ganglidiomab: Results from Compassionate-Use Treatments

The Immunocytokine FAP-IL-2v Enhances Anti-Neuroblastoma Efficacy of the Anti-GD2 Antibody Dinutuximab Beta

Clinical Phenotype and Management of Severe Neurotoxicity Observed in Patients with Neuroblastoma Treated with Dinutuximab Beta in Clinical Trials

Comparison of three different methods to detect bone marrow involvement in patients with neuroblastoma.

Collaborators (10)

Angelika Eggert

William Anderson

Bernhard Rauch

Adela Cañete

Johannes Hubertus Schulte

Lea Miebach

Matthias Eyrich

Peter Lang

Eric Freund

Aleksandra Wieczorek

Make your next move.